Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Regional iron distribution and soluble ferroprotein profiles in the healthy human brain.

McAllum EJ, Hare DJ, Volitakis I, McLean CA, Bush AI, Finkelstein DI, Roberts BR.

Prog Neurobiol. 2020 Mar;186:101744. doi: 10.1016/j.pneurobio.2019.101744. Epub 2019 Dec 20.

PMID:
31870805
2.

Characterising the brain metalloproteome in Down syndrome patients with concomitant Alzheimer's pathology.

Malakooti N, Roberts B, Pritchard MA, Volitakis I, Kim RC, Lott IT, McLean CA, Finkelstein DI, Adlard PA.

Metallomics. 2020 Jan 29;12(1):114-132. doi: 10.1039/c9mt00196d.

PMID:
31764918
3.

CuII (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease.

Southon A, Szostak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, Barnham KJ, Crouch PJ, Ayton S, Donnelly PS, Bush AI.

Br J Pharmacol. 2020 Feb;177(3):656-667. doi: 10.1111/bph.14881. Epub 2020 Jan 14.

PMID:
31655003
4.

The Down Syndrome-Associated Protein, Regulator of Calcineurin-1, is Altered in Alzheimer's Disease and Dementia with Lewy Bodies.

N M; AIBL Research Group, C F, I V, Ca M, Rc K, Ai B, A R, Ma P, DI F, Pa A.

J Alzheimers Dis Parkinsonism. 2019;9(2). pii: 462. doi: 10.4172/2161-0460.1000462. Epub 2019 Mar 6.

5.

The Effects of Clioquinol on P-glycoprotein Expression and Biometal Distribution in the Mouse Brain Microvasculature.

McInerney MP, Pan Y, Volitakis I, Bush AI, Short JL, Nicolazzo JA.

J Pharm Sci. 2019 Jul;108(7):2247-2255. doi: 10.1016/j.xphs.2019.01.030. Epub 2019 Feb 7.

PMID:
30738852
6.

Zn-DTSM, A Zinc Ionophore with Therapeutic Potential for Acrodermatitis Enteropathica?

Bray L, Volitakis I, Ayton S, Bush AI, Adlard PA.

Nutrients. 2019 Jan 21;11(1). pii: E206. doi: 10.3390/nu11010206.

7.

Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells.

McInerney MP, Volitakis I, Bush AI, Banks WA, Short JL, Nicolazzo JA.

Pharm Res. 2018 Mar 5;35(4):83. doi: 10.1007/s11095-018-2377-6.

PMID:
29508078
8.

Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux.

Acevedo KM, Hayne DJ, McInnes LE, Noor A, Duncan C, Moujalled D, Volitakis I, Rigopoulos A, Barnham KJ, Villemagne VL, White AR, Donnelly PS.

J Med Chem. 2018 Feb 8;61(3):711-723. doi: 10.1021/acs.jmedchem.7b01158. Epub 2018 Jan 8.

PMID:
29232129
9.

A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort.

Pedrini S, Gupta VB, Hone E, Doecke J, O'Bryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN; AIBL Research Group.

Sci Rep. 2017 Oct 25;7(1):14057. doi: 10.1038/s41598-017-14020-9.

10.

The APOE ε4 Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimer's Disease.

R Cardoso B, Hare DJ, Lind M, McLean CA, Volitakis I, Laws SM, Masters CL, Bush AI, Roberts BR.

ACS Chem Neurosci. 2017 Jul 19;8(7):1459-1464. doi: 10.1021/acschemneuro.7b00014. Epub 2017 May 3.

PMID:
28453930
11.

Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid.

Roberts BR, Doecke JD, Rembach A, Yévenes LF, Fowler CJ, McLean CA, Lind M, Volitakis I, Masters CL, Bush AI, Hare DJ; AIBL research group.

Acta Neuropathol Commun. 2016 Nov 14;4(1):119.

12.

Lithium suppression of tau induces brain iron accumulation and neurodegeneration.

Lei P, Ayton S, Appukuttan AT, Moon S, Duce JA, Volitakis I, Cherny R, Wood SJ, Greenough M, Berger G, Pantelis C, McGorry P, Yung A, Finkelstein DI, Bush AI.

Mol Psychiatry. 2017 Mar;22(3):396-406. doi: 10.1038/mp.2016.96. Epub 2016 Jul 12.

13.

Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.

Denoyer D, Pearson HB, Clatworthy SA, Smith ZM, Francis PS, Llanos RM, Volitakis I, Phillips WA, Meggyesy PM, Masaldan S, Cater MA.

Oncotarget. 2016 Jun 14;7(24):37064-37080. doi: 10.18632/oncotarget.9245.

14.

Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing.

Hare DJ, Faux NG, Roberts BR, Volitakis I, Martins RN, Bush AI.

Metallomics. 2016 Jun 1;8(6):628-32. doi: 10.1039/c6mt00019c.

PMID:
26962965
15.

Effects of Neonatal Iron Feeding and Chronic Clioquinol Administration on the Parkinsonian Human A53T Transgenic Mouse.

Billings JL, Hare DJ, Nurjono M, Volitakis I, Cherny RA, Bush AI, Adlard PA, Finkelstein DI.

ACS Chem Neurosci. 2016 Mar 16;7(3):360-6. doi: 10.1021/acschemneuro.5b00305. Epub 2016 Jan 7.

PMID:
26712118
16.

Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months.

Thai C, Lim YY, Villemagne VL, Laws SM, Ames D, Ellis KA, Rainey-Smith SR, Martins RN, Masters CL, Rowe CC, Maruff P; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group.

PLoS One. 2015 Oct 2;10(10):e0139082. doi: 10.1371/journal.pone.0139082. eCollection 2015.

17.

Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.

Leifert WR, Nguyen T, Rembach A, Martins R, Rainey-Smith S, Masters CL, Ames D, Rowe CC, Macaulay SL, François M, Fenech MF; Australian Imaging, Biomarkers and Lifestyle Study Research Group.

J Alzheimers Dis. 2015;48(2):443-52. doi: 10.3233/JAD-150330.

PMID:
26402008
18.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938
19.

Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease.

Liang SH, Southon AG, Fraser BH, Krause-Heuer AM, Zhang B, Shoup TM, Lewis R, Volitakis I, Han Y, Greguric I, Bush AI, Vasdev N.

ACS Med Chem Lett. 2015 Aug 10;6(9):1025-9. doi: 10.1021/acsmedchemlett.5b00281. eCollection 2015 Sep 10.

20.

Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β-Amyloid Toxicity and Are Mediated by Tau.

Li X, Lei P, Tuo Q, Ayton S, Li QX, Moon S, Volitakis I, Liu R, Masters CL, Finkelstein DI, Bush AI.

Neurotherapeutics. 2015 Oct;12(4):862-73. doi: 10.1007/s13311-015-0378-2.

21.

Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.

Lei P, Ayton S, Appukuttan AT, Volitakis I, Adlard PA, Finkelstein DI, Bush AI.

Neurobiol Dis. 2015 Sep;81:168-75. doi: 10.1016/j.nbd.2015.03.015. Epub 2015 Mar 18.

PMID:
25796563
22.

Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.

Berggren KL, Chen J, Fox J, Miller J, Dodds L, Dugas B, Vargas L, Lothian A, McAllum E, Volitakis I, Roberts B, Bush AI, Fox JH.

Redox Biol. 2015;4:363-74. doi: 10.1016/j.redox.2015.02.002. Epub 2015 Feb 11.

23.

Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.

Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Restrepo C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P; Australian Imaging, Biomarkers, and Lifestyle Research Group.

JAMA Psychiatry. 2015 Mar;72(3):284-91. doi: 10.1001/jamapsychiatry.2014.2476.

PMID:
25629787
24.

Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation.

Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR.

ACS Chem Neurosci. 2015 Mar 18;6(3):398-402. doi: 10.1021/cn5003557. Epub 2015 Jan 23.

PMID:
25588002
25.

Motor and cognitive deficits in aged tau knockout mice in two background strains.

Lei P, Ayton S, Moon S, Zhang Q, Volitakis I, Finkelstein DI, Bush AI.

Mol Neurodegener. 2014 Aug 14;9:29. doi: 10.1186/1750-1326-9-29.

26.

Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.

Lu Z, Marks E, Chen J, Moline J, Barrows L, Raisbeck M, Volitakis I, Cherny RA, Chopra V, Bush AI, Hersch S, Fox JH.

Neurobiol Dis. 2014 Nov;71:34-42. doi: 10.1016/j.nbd.2014.06.022. Epub 2014 Jul 8.

PMID:
25014023
27.

Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease.

Ayton S, Lei P, Adlard PA, Volitakis I, Cherny RA, Bush AI, Finkelstein DI.

Mol Neurodegener. 2014 Jul 10;9:27. doi: 10.1186/1750-1326-9-27.

28.

X-ray fluorescence imaging reveals subcellular biometal disturbances in a childhood neurodegenerative disorder.

Grubman A, James SA, James J, Duncan C, Volitakis I, Hickey JL, Crouch PJ, Donnelly PS, Kanninen KM, Liddell JR, Cotman SL, de Jonge, White AR.

Chem Sci. 2014 Jun;5(6):2503-2516.

29.

Deregulation of biometal homeostasis: the missing link for neuronal ceroid lipofuscinoses?

Grubman A, Pollari E, Duncan C, Caragounis A, Blom T, Volitakis I, Wong A, Cooper J, Crouch PJ, Koistinaho J, Jalanko A, White AR, Kanninen KM.

Metallomics. 2014 Apr;6(4):932-43.

PMID:
24804307
30.

Decreased serum zinc is an effect of ageing and not Alzheimer's disease.

Rembach A, Hare DJ, Doecke JD, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR.

Metallomics. 2014 Jul;6(7):1216-9. doi: 10.1039/c4mt00060a.

PMID:
24676028
31.

Ceruloplasmin gene-deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution.

Gresle MM, Schulz K, Jonas A, Perreau VM, Cipriani T, Baxter AG, Miranda-Hernandez S, Field J, Jokubaitis VG, Cherny R, Volitakis I, David S, Kilpatrick TJ, Butzkueven H.

J Neurosci Res. 2014 Jun;92(6):732-42. doi: 10.1002/jnr.23349. Epub 2014 Jan 27.

PMID:
24615902
32.

Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation.

Bica L, Liddell JR, Donnelly PS, Duncan C, Caragounis A, Volitakis I, Paterson BM, Cappai R, Grubman A, Camakaris J, Crouch PJ, White AR.

PLoS One. 2014 Feb 28;9(2):e90070. doi: 10.1371/journal.pone.0090070. eCollection 2014.

33.

Deregulation of subcellular biometal homeostasis through loss of the metal transporter, Zip7, in a childhood neurodegenerative disorder.

Grubman A, Lidgerwood GE, Duncan C, Bica L, Tan JL, Parker SJ, Caragounis A, Meyerowitz J, Volitakis I, Moujalled D, Liddell JR, Hickey JL, Horne M, Longmuir S, Koistinaho J, Donnelly PS, Crouch PJ, Tammen I, White AR, Kanninen KM.

Acta Neuropathol Commun. 2014 Feb 28;2:25. doi: 10.1186/2051-5960-2-25.

34.

Increased metal content in the TDP-43(A315T) transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Dang TN, Lim NK, Grubman A, Li QX, Volitakis I, White AR, Crouch PJ.

Front Aging Neurosci. 2014 Feb 11;6:15. doi: 10.3389/fnagi.2014.00015. eCollection 2014.

35.

MR-less surface-based amyloid assessment based on 11C PiB PET.

Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, Ames D, Masters CL, Ellis KA, Villemagne VL, Rowe CC, Fripp J; AIBL Research Group.

PLoS One. 2014 Jan 10;9(1):e84777. doi: 10.1371/journal.pone.0084777. eCollection 2014.

36.

Altered transition metal homeostasis in Niemann-Pick disease, type C1.

Hung YH, Faux NG, Killilea DW, Yanjanin N, Firnkes S, Volitakis I, Ganio G, Walterfang M, Hastings C, Porter FD, Ory DS, Bush AI.

Metallomics. 2014 Mar;6(3):542-53. doi: 10.1039/c3mt00308f. Epub 2013 Dec 16.

37.

Iron accumulates in Huntington's disease neurons: protection by deferoxamine.

Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, Volitakis I, Bush AI, Hersch S, Fox JH.

PLoS One. 2013 Oct 11;8(10):e77023. doi: 10.1371/journal.pone.0077023. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/67f555f5-35b7-4468-8bab-26d518942803.

38.

Increased risk of cognitive impairment in patients with diabetes is associated with metformin.

Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, Faux NG, Martins R, Szoeke C, Rowe C, Watters DA; AIBL Investigators.

Diabetes Care. 2013 Oct;36(10):2981-7. doi: 10.2337/dc13-0229. Epub 2013 Sep 5. Erratum in: Diabetes Care. 2013 Nov;36(11):3850.

39.

Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis.

Kanninen KM, Grubman A, Caragounis A, Duncan C, Parker SJ, Lidgerwood GE, Volitakis I, Ganio G, Crouch PJ, White AR.

Biol Open. 2013 May 20;2(6):635-46. doi: 10.1242/bio.20134804. Print 2013 Jun 15.

40.

Copper modulates the large dense core vesicle secretory pathway in PC12 cells.

Duncan C, Bica L, Crouch PJ, Caragounis A, Lidgerwood GE, Parker SJ, Meyerowitz J, Volitakis I, Liddell JR, Raghupathi R, Paterson BM, Duffield MD, Cappai R, Donnelly PS, Grubman A, Camakaris J, Keating DJ, White AR.

Metallomics. 2013 Jun;5(6):700-14. doi: 10.1039/c3mt20231c.

PMID:
23661118
41.

A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.

Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe CC, Salvado O, Macaulay SL, Masters CL, Villemagne VL; Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle Study Research Group.

Mol Psychiatry. 2014 Apr;19(4):519-26. doi: 10.1038/mp.2013.40. Epub 2013 Apr 30.

PMID:
23628985
42.

Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis.

Kanninen KM, Grubman A, Meyerowitz J, Duncan C, Tan JL, Parker SJ, Crouch PJ, Paterson BM, Hickey JL, Donnelly PS, Volitakis I, Tammen I, Palmer DN, White AR.

PLoS One. 2013;8(3):e58644. doi: 10.1371/journal.pone.0058644. Epub 2013 Mar 14.

43.

Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.

Liddell JR, Obando D, Liu J, Ganio G, Volitakis I, Mok SS, Crouch PJ, White AR, Codd R.

Free Radic Biol Med. 2013 Jul;60:147-56. doi: 10.1016/j.freeradbiomed.2013.01.027. Epub 2013 Feb 4.

PMID:
23391576
44.

Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease.

Rembach A, Doecke JD, Roberts BR, Watt AD, Faux NG, Volitakis I, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Wilson W, Ellis KA, Martins RN, Rowe CC, Villemagne VL, Ames D, Masters CL, AIBL research group, Bush AI.

J Alzheimers Dis. 2013;34(1):171-82. doi: 10.3233/JAD-121474.

PMID:
23168449
45.

Blood-based protein biomarkers for diagnosis of Alzheimer disease.

Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group.

Arch Neurol. 2012 Oct;69(10):1318-25.

46.

Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.

Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI.

Nat Med. 2012 Jan 29;18(2):291-5. doi: 10.1038/nm.2613.

PMID:
22286308
47.

Elevated labile Cu is associated with oxidative pathology in Alzheimer disease.

James SA, Volitakis I, Adlard PA, Duce JA, Masters CL, Cherny RA, Bush AI.

Free Radic Biol Med. 2012 Jan 15;52(2):298-302. doi: 10.1016/j.freeradbiomed.2011.10.446. Epub 2011 Oct 24.

PMID:
22080049
48.

Mechanisms controlling the cellular accumulation of copper bis(thiosemicarbazonato) complexes.

Price KA, Crouch PJ, Volitakis I, Paterson BM, Lim S, Donnelly PS, White AR.

Inorg Chem. 2011 Oct 3;50(19):9594-605. doi: 10.1021/ic201334q. Epub 2011 Sep 1.

PMID:
21882803
49.

The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.

Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, Greenough MA, Volitakis I, Adlard PA, Cherny RA, Masters CL, Bush AI, Barnham KJ, White AR.

J Neurochem. 2011 Oct;119(1):220-30. doi: 10.1111/j.1471-4159.2011.07402.x. Epub 2011 Aug 25.

50.

Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.

Fox JH, Connor T, Stiles M, Kama J, Lu Z, Dorsey K, Lieberman G, Sapp E, Cherny RA, Banks M, Volitakis I, DiFiglia M, Berezovska O, Bush AI, Hersch SM.

J Biol Chem. 2011 May 20;286(20):18320-30. doi: 10.1074/jbc.M110.199448. Epub 2011 Mar 30. Erratum in: J Biol Chem. 2011 Jul 29;286(30):27068. Liebermann, Gregory [corrected to Lieberman, Gregory].

Supplemental Content

Loading ...
Support Center